# Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

> **NCT02017457** · PHASE2 · COMPLETED · sponsor: **Carlos Graux, MD, PhD** · enrollment: 50 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **BIOLOGICAL:** Donor lymphocyte infusion
- **DRUG:** Azacytidine

## Key facts

- **NCT ID:** NCT02017457
- **Lead sponsor:** Carlos Graux, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2019-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02017457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02017457, "Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02017457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*